Investigational drug · Phase 3
AL8326
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
9
Any phase or sponsor naming "AL8326"
First trial start
2021
Oct 26, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AL8326", any sponsor or status.
Conditions studied
As listed on its trial records.
- Endometrial Neoplasms
- Soft Tissue Sarcoma (STS)
- Breast Neoplasms
- Small Cell Lung Carcinoma
- Solid Tumor
- Small Cell Lung Cancer
- Renal Cell Carcinoma (RCC)
- Non-Small Cell Lung
Approved drugs for the same conditions: Small cell lung cancer · Kidney cancer (renal cell carcinoma) · Endometrial cancer · Sarcoma · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "AL8326" as an intervention, largest first.
- A Phase IIII Study of AL8326 in Small Cell Lung CancerPivotal-lookingRecruiting
Advenchen Laboratories Nanjing Ltd.Industry
NCT06247605 · 243 participants (planned) · Start Oct 26, 2023 · Primary completion Jul 2028
Drug: AL8326 tablets; placebo · For: Small Cell Lung Carcinoma
Sites: Changchun, China
Advenchen Laboratories Nanjing Ltd.Industry
NCT04890795 · 237 participants (planned) · Start Oct 19, 2020 · Primary completion Sep 2021
Drug: AL8326 tablets · For: Small Cell Lung Cancer
Sites: Bengbu, China; Zhengzhou, China; Nanjing, China · 9 sites in all
- A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.Recruiting
Advenchen Laboratories, LLCIndustry
NCT07392736 · 228 participants (planned) · Start Oct 26, 2021 · Primary completion Nov 7, 2029
Drug: AL8326 tablets; Toripalimab · For: Solid Tumor
Sites: Beijing, China; Hunan, China; Fuzhou, China · 15 sites in all
- A Study of AL8326 in Non-Small Cell Lung CancerActive, not recruiting
Advenchen Laboratories, LLCIndustry
NCT06794957 · 158 participants (planned) · Start May 19, 2022 · Primary completion Dec 2027
Drug: AL8326 tablets · For: Non-small Cell Lung Cancer
Sites: Bengbu, China; Hefei, China; Xuancheng, China · 10 sites in all
- A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast CancersNot yet recruiting
Advenchen Pharmaceuticals, LLC.Industry
NCT07811232 · 138 participants (planned) · Start Sep 1, 2026 · Primary completion Sep 1, 2030
Drug: AL58805; AL8326 and 2 more · For: Endometrial Neoplasms; Soft Tissue Sarcoma (STS); Breast Neoplasms
Sites: Houston, Texas
Advenchen Pharmaceuticals, LLC.Industry
NCT05363280 · 80 participants (planned) · Start Nov 1, 2022 · Primary completion Dec 2027
Drug: AL8326 40 mg; AL8326 60 mg and 1 more · For: Small Cell Lung Cancer; Renal Cell Carcinoma (RCC); Non-Small Cell Lung
Sites: Birmingham, Alabama; Weston, Florida; Chicago, Illinois · 7 sites in all
- A Phase I Study of AL8326 in Advanced Solid TumorStatus unknown
Advenchen Laboratories Nanjing Ltd.Industry
NCT04890587 · 40 participants (planned) · Start Aug 17, 2017 · Primary completion Dec 2023
Drug: AL8326 tablets · For: Advanced Solid Tumors
Sites: Changsha, China; Qingdao, China
Advenchen Laboratories Nanjing Ltd.Industry
NCT05486598 · 16 participants (planned) · Start Jun 21, 2022 · Primary completion Dec 2022
Drug: AL8326 tablets · For: Diet, High-Fat; Pharmacokinetics
Sites: Qingdao, China
Advenchen Laboratories Nanjing Ltd.Industry
NCT07132957 · 6 participants · Start Feb 21, 2025 · Primary completion May 17, 2025
Drug: 14C-labeled AL8326 · For: Small Cell Lung Cancer; Solid Tumors
Sites: Suzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Endometrial Neoplasms
- Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms
- OlomorasibLY3537982Phase 36 trials
Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis
- AL58805Phase 22 trials
Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- DM002Phase 21 trial
Xadcera Biopharmaceutical (Suzhou) Co., Ltd. · Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms
- E7386Phase 21 trial
Eisai · Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.